Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

FDA approves new oral medication for renal cell carcinoma

FDA approves new oral medication for renal cell carcinoma

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

HemoRANK-TKI in vitro assay service package from ReachBio

HemoRANK-TKI in vitro assay service package from ReachBio

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Onyx Pharmaceuticals files complaint against Bayer on fluoro-sorafenib

Onyx Pharmaceuticals files complaint against Bayer on fluoro-sorafenib

Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma

Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma